Drug Profile
Research programme: cancer therapy - STIL BioTechnologies
Alternative Names: SB 144; SSP 1; SSP 5; YM 17; YM 27Latest Information Update: 26 Jan 2007
Price :
$50
*
At a glance
- Originator STIL BioTechnologies
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 16 Jul 2003 Preclinical trials in Non-small cell lung cancer in Israel (unspecified route)